New Delhi, April 14 -- Danish drugmaker Novo Nordisk on Tuesday announced that it is collaborating with ChatGPT's parent company, OpenAI, to bring "new and better treatment options to patients faster," CNBC reported.

In a statement, Novo Nordisk said that its partnership with Sam Altman-led OpenAI will help the drugmaker to better use artificial intelligence (AI) to analyse complex datasets, help identify promising new drugs, and bring down the time it takes for a medicine to move from the research stage to patient use.

Pilot programmes will be launched across research and development, manufacturing and commercial operations, with full integration by the end of 2026, The Wall Street Journal reported.

Novo CEO Mike Doustdar said, "There...